PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Status:
Active, not recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in
patients with HER2-positive advanced or metastatic solid tumors.